This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Patients with HPV16+ cervical cancer and high T-cell responses to an HPV16 vaccine survived longer.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
May 2020
Volume 10, Issue 5
Volume 10, Issue 5
Strong HPV Vaccine Response Predicts Better Survival with Chemotherapy
Jump to section
Advertisement